Peter R. Galle

Hepatology · 2002–2022

A researcher in the Science corpus: 19 papers; trusts 3 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 249 citations into it; #147 of 151 by trust here, #19 by citations
• Epidemiology — 137 citations into it

Whom Peter R. Galle trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Llovet
2. Jordi Bruix1 , 2
3. Riccardo Lencioni
4. F. Kanwal
5. H. B. EL‐SERAG
6. Alejandro Forner1 , 2
7. G. Guyatt
8. Andrew X. Zhu
9. A. Cheng

Who trusts Peter R. Galle overall

1. Amit G. Singal
2. J. Llovet

Papers from Peter R. Galle's perspective

Ordered by how strongly the researchers Peter R. Galle trusts endorse each paper. Same corpus, a different order for every researcher.

1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
4. Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
5. INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
6. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. (Gastroenterology)
7. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
8. The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
9. Use of archived specimens in evaluation of prognostic and predictive biomarkers. (Journal of the National Cancer Institute)
10. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)

Their papers

• TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling (2004) — 676 citations
• Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7 (2004) — 1,277 citations
• LASS6, an additional member of the longevity assurance gene family. (2005) — 20 citations
• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. (2022) — 1,114 citations
• Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. (2021) — 1,360 citations
• BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. (2021) — 2,982 citations
• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. (2020) — 5,608 citations
• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) — 1,383 citations
• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018) — 8,228 citations
• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. (2014) — 1,356 citations
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012) — 790 citations
• Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) — 653 citations
• Simplified criteria for the diagnosis of autoimmune hepatitis (2008) — 1,779 citations
• Sorafenib in advanced hepatocellular carcinoma. (2008) — 6,212 citations
• Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. (2004) — 937 citations
• Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. (2003) — 951 citations
• CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. (2003) — 822 citations
• Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet (2002) — 682 citations